Perimeter Solutions (PRM) M&A Announcement summary
Event summary combining transcript, slides, and related documents.
M&A Announcement summary
12 Dec, 2025Deal rationale and strategic fit
Acquisition of MMT, a leader in precision machinery and consumables for minimally invasive medical device manufacturing, for $685 million in cash, aligns with a strategy to own high-quality, capital-light businesses with strong recurring and proprietary aftermarket revenue.
The deal supports a decentralized operating structure and Value Driver strategy, emphasizing customer value, compliance, and operational improvements.
MMT's deep relationships with blue-chip OEMs and history of successful tuck-in M&A are expected to drive continued organic and acquisition-led growth.
The acquisition targets expansion in the medical technology sector and aims for private-equity-like returns.
MMT will operate as a standalone business, maintaining autonomy and accountability within a decentralized structure.
Financial terms and conditions
Purchase price is $685 million in cash, funded by $500 million in new secured debt and $185 million of cash on hand, with certain tax benefits.
MMT is projected to generate $140 million in revenue and $50 million in Adjusted EBITDA in 2025.
Implied purchase price multiple is approximately 14x Adjusted EBITDA.
Pro forma leverage at closing is projected at 2.7x net debt to combined Adjusted EBITDA.
No equity issuance; company retains ample liquidity and balance sheet flexibility post-acquisition.
Synergies and expected cost savings
Value creation is expected through the Value Driver operating model, focusing on customer value, productivity, and margin improvement.
Aftermarket consumables and services, accounting for about half of revenue, provide recurring income and margin stability.
Latest events from Perimeter Solutions
- Q2 2026 net sales up 31%, adjusted EBITDA up 16%, with Monaco acquisition set to drive growth.PRM
Q2 2026 - Q1 2026 net sales up 74% and adjusted EBITDA up 128%, driven by acquisitions and contracts.PRM
Q1 2026 - Shareholders to vote on directors, executive pay, and auditor amid strong sales and EBITDA growth.PRM
Proxy filing - Director elections, executive pay, and auditor ratification are up for shareholder vote.PRM
Proxy filing - 2025 revenue up 16%, Specialty Products surged, MMT acquired, leverage and net loss increased.PRM
Q4 2025 - Q2 2024 sales up 67%, Adjusted EBITDA up 209%, but net income down 58% on higher advisory fees.PRM
Q2 2024 - Q3 2024 sales and EBITDA more than doubled, but non-recurring charges led to a net loss.PRM
Q3 2024 - Market leadership, value-driven growth, and high barriers fuel sustained financial outperformance.PRM
UBS Global Materials Conference - Adjusted EBITDA up 190% to $280M in 2024, driven by Fire Safety and strategic investments.PRM
Q4 2024